Alkermes Raises Revenue Forecast After Arbitration Award
Biopharmaceutical company Alkermes PLC on Tuesday boosted its financial forecast for 2023 by $425 million after the company said it wrapped arbitration proceedings with Johnson & Johnson subsidiary Janssen Pharmaceutica NV...To view the full article, register now.
Already a subscriber? Click here to view full article